Detalhe da pesquisa
1.
Pharmacogenetics testing (DPYD and UGT1A1) for fluoropyrimidine and irinotecan in routine clinical care: Perspectives of medical oncologists and oncology pharmacists.
J Oncol Pharm Pract
; 30(1): 30-37, 2024 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-37021580
2.
A systematic review and meta-analysis of toxicity and treatment outcomes with pharmacogenetic-guided dosing compared to standard of care BSA-based fluoropyrimidine dosing.
Br J Cancer
; 127(1): 126-136, 2022 07.
Artigo
Inglês
| MEDLINE | ID: mdl-35306539
3.
A randomised controlled trial of clinical pharmacy intervention versus standard care to improve medication adherence in outpatients with head and neck cancer receiving radiotherapy.
Support Care Cancer
; 30(5): 4243-4253, 2022 May.
Artigo
Inglês
| MEDLINE | ID: mdl-35091845
4.
Pharmacogenomics guided dosing for fluoropyrimidine and irinotecan chemotherapies for patients with cancer (PACIFIC-PGx): study protocol of a multicentre clinical trial.
Acta Oncol
; 61(9): 1136-1139, 2022 09.
Artigo
Inglês
| MEDLINE | ID: mdl-35972781
5.
Patient and healthcare professional acceptability of pharmacogenetic screening for DPYD and UGT1A1: A cross sectional survey.
Clin Transl Sci
; 16(12): 2700-2708, 2023 12.
Artigo
Inglês
| MEDLINE | ID: mdl-37877594
6.
Cancer patients' perspectives on participating in a community pharmacy-based hyperglycaemia screening service - A qualitative exploration of enablers and barriers.
Res Social Adm Pharm
; 17(3): 613-618, 2021 03.
Artigo
Inglês
| MEDLINE | ID: mdl-32563743